Donald Keyser Biography and Net Worth

Director of Lantern Pharma

Dr. Keyser has served as a director since January 2018 and Chairman since November 2019. Dr. Keyser founded and has served from 2017 as director, president and chief operating officer of Renibus Therapeutics, a company developing novel therapies for the diagnosis, treatment and prevention of kidney disease. Dr. Keyser also founded ZS Pharma and served since 2008 as a director and chief operating officer of that company until December 2015 when it was acquired by Astra Zeneca for $2.7 Billion. Dr. Keyser was the inventor of the Mucinex product line for Adams Respiratory Therapeutics. Dr. Keyser developed and executed the R&D and Regulatory strategy for Adams Respiratory Therapeutics as Vice President of Development and Regulatory Affairs during his period there from 1998 to 2004. Adams Respiratory Therapeutics was acquired by Reckitt Benckiser for $2.3 Billion. He was previously employed as Chief Compliance Officer & Vice President Regulatory Affairs, Encysive Pharmaceuticals, Vice President Technical & Regulatory Affairs, Medeva Americas, Sr. Director Regulatory Affairs, Marion Merrell Dow and Regulatory Principal, Abbott Laboratories.

Dr. Keyser received his Pharmacy degree from Creighton University, a Juris Doctorate from Creighton University, a MPA from the University of Missouri-Kansas City and a PhD in Economics from The University of Texas at Dallas.

What is Donald Jeffrey Keyser's net worth?: The estimated net worth of Donald Jeffrey Keyser is at least $91.66 thousand as of May 12th, 2026. Dr. Keyser owns 94,303 shares of Lantern Pharma stock worth more than $91,663 as of October 6th. This net worth approximation does not reflect any other investments that Dr. Keyser may own. Learn More about Donald Jeffrey Keyser's net worth.
How do I contact Donald Jeffrey Keyser?: The corporate mailing address for Dr. Keyser and other Lantern Pharma executives is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. Lantern Pharma can also be reached via phone at 972-277-1136 and via email at [email protected]. Learn More on Donald Jeffrey Keyser's contact information.
Has Donald Jeffrey Keyser been buying or selling shares of Lantern Pharma?: Donald Jeffrey Keyser has not been actively trading shares of Lantern Pharma over the course of the past ninety days. Most recently, on Tuesday, May 12th, Donald Jeffrey Keyser bought 48,544 shares of Lantern Pharma stock. The stock was acquired at an average cost of $2.06 per share, with a total value of $100,000.64. Following the completion of the transaction, the director now directly owns 94,303 shares of the company's stock, valued at $194,264.18. Learn More on Donald Jeffrey Keyser's trading history.
Who are Lantern Pharma's active insiders?: Lantern Pharma's insider roster includes Donald Keyser (Director), and Lee Schalop (Director). Learn More on Lantern Pharma's active insiders.
Are insiders buying or selling shares of Lantern Pharma?: In the last year, Lantern Pharma insiders bought shares 2 times. They purchased a total of 97,088 shares worth more than $200,001.28. The most recent insider tranaction occured on May, 12th when Director Lee Troy Schalop bought 48,544 shares worth more than $100,000.64. Insiders at Lantern Pharma own 8.5% of the company. Learn More about insider trades at Lantern Pharma.
Information on this page was last updated on 5/12/2026.

Donald Jeffrey Keyser Insider Trading History at Lantern Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/12/2026	Buy	48,544	$2.06	$100,000.64	94,303

Donald Jeffrey Keyser Buying and Selling Activity at Lantern Pharma

Lantern Pharma Company Overview

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Today's Range

Now: $0.95

$0.92

$1.07

50 Day Range

MA: $2.01

$0.86

$2.86

2 Week Range

Now: $0.95

$0.84

$4.70

Volume

388,626 shs

Average Volume

315,369 shs

Market Capitalization

$12.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.33